Evidence map›Paper›PMID 37875547›Full record

ArticleScientific reports2023

In silico engineering and simulation of RNA interferences nanoplatforms for osteoporosis treating and bone healing promoting.

Aylar Imanpour, Hanieh Kolahi Azar, Dorna Makarem, Zeinab Nematollahi, Reza Nahavandi, Mohammadreza Rostami, Nima Beheshtizadeh

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Molecular-level understanding of the aging bone and regeneration mechanisms using computational methods.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Aylar ImanpourRegenerative Medicine Group (REMED), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Hanieh Kolahi AzarRegenerative Medicine Group (REMED), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Dorna MakaremEscuela Tecnica Superior de Ingenieros de Telecomunicacion, Politecnica de Madrid, Madrid, Spain.
Zeinab NematollahiUCL Department of Nanotechnology, Division of Surgery and Interventional Science, University College London, London, UK.
Reza NahavandiRegenerative Medicine Group (REMED), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Mohammadreza RostamiFood Science and Nutrition Group (FSAN), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Nima BeheshtizadehRegenerative Medicine Group (REMED), Universal Scientific Education and Research Network (USERN), Tehran, Iran. n-beheshtizadeh@razi.tums.ac.ir.
Tehran University of Medical Sciences · IRUniversal Scientific Education and Research Network · IRTabriz University of Medical Sciences · IRUniversidad Politécnica de Madrid · ESUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis is a bone condition characterized by reduced bone mineral density (BMD), poor bone microarchitecture/mineralization, and/or diminished bone strength. This asymptomatic disorder typically goes untreated until it presents as a low-trauma fracture of the hip, spine, proximal humerus, pelvis, and/or wrist, requiring surgery. Utilizing RNA interference (RNAi) may be accomplished in a number of ways, one of which is by the use of very tiny RNA molecules called microRNAs (miRNAs) and small interfering RNAs (siRNAs). Several kinds of antagomirs and siRNAs are now being developed to prevent the detrimental effects of miRNAs. The goal of this study is to find new antagonists for miRNAs and siRNAs that target multiple genes in order to reduce osteoporosis and promote bone repair. Also, choosing the optimum nanocarriers to deliver these RNAis appropriately to the body could lighten up the research road. In this context, we employed gene ontology analysis to search across multiple datasets. Following data analysis, a systems biology approach was used to process it. A molecular dynamics (MD) simulation was used to explore the possibility of incorporating the suggested siRNAs and miRNA antagonists into polymeric bioresponsive nanocarriers for delivery purposes. Among the three nanocarriers tested [polyethylene glycol (PEG), polyethylenimine (PEI), and PEG-PEI copolymer], MD simulations show that the integration of PEG-PEI with has-mIR-146a-5p is the most stable (total energy = -372.84 kJ/mol, Gyration radius = 2.1084 nm), whereas PEI is an appropriate delivery carrier for has-mIR-7155. The findings of the systems biology and MD simulations indicate that the proposed RNAis might be given through bioresponsive nanocarriers to accelerate bone repair and osteoporosis treatment.

Indexed as

MicroRNAsOsteoporosisBone DensityHumansPolyethylene GlycolsPolyethyleneiminePolymersRNA InterferenceRNA, Small InterferingMicroRNAspoly(ethylene glycol)-co-poly(ethyleneimine)Polyethylene GlycolsPolyethyleneiminePolymersRNA, Small Interfering

Identifiers

PMID37875547
PMCPMC10598124
OpenAlexW4387909166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.